新型吸入性可溶性鸟苷酸环化酶激活剂mosliciguat在健康成人中的安全性与药代动力学
该研究包含三项随机、单盲、安慰剂对照的1期试验,评估吸入干粉剂mosliciguat在健康男性中的安全性与药代动力学。结果显示mosliciguat总体耐受良好,多数不良事件为轻度,无严重不良事件,无支气管痉挛或气道刺激相关事件,药效学反应提示sGC激活及支气管舒张作用。
要点
- mosliciguat干粉吸入剂在健康男性中总体耐受良好,多数不良事件为轻度。
- 未观察到临床相关的肺功能损害或血氧饱和度变化。
- 药代动力学特征适合吸入治疗,全身暴露低,提示肺选择性递送。
核心结论
- mosliciguat干粉吸入剂在健康受试者中耐受良好,无支气管痉挛或气道刺激相关不良事件。
- 药效学反应提示sGC激活及支气管舒张作用。
研究设计与样本
- 三项随机、单盲、安慰剂对照的1期研究,对象为健康男性。
- 单剂量递增研究纳入78例,mosliciguat剂量60-4000 μg。
- 多剂量递增研究纳入36例,每日一次480-2000 μg,共8天。
- 多剂量研究纳入21例,mosliciguat 1000 μg,共14天。
主要发现
- 多数不良事件为轻度,无严重不良事件或导致停药的不良事件。
- 未观察到临床相关的肺功能损害或血氧饱和度变化。
- 多剂量递增研究中,给药后6小时体描记法显示气道阻力降低。
- 总体上未见临床相关的血压影响,但单剂量递增研究和多剂量研究中较高剂量下出现少数轻至中度直立性低血压事件。
- 单剂量递增研究中,mosliciguat引起小幅、剂量依赖性的心率增加。
关键数值与推荐
- 血浆环磷酸鸟苷水平升高证实mosliciguat与靶点结合。
- 药代动力学特征适合吸入治疗,表现为全身暴露低。
临床怎么用
- 该1期健康人数据支持mosliciguat干粉吸入剂后续在肺动脉高压患者中开展临床研究。
- 吸入给药可能实现比全身性sGC刺激剂更靶向的肺部递送。
局限性
- 研究仅纳入健康男性受试者,未涉及患者人群。
- 为1期研究,样本量有限,安全性结论需在更大规模及患者人群中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Br J Clin Pharmacol. 2026 Nov;92(11):4003-4016. doi: 10.1002/bcp.70668. Epub 2026 Jul 23. ABSTRACT AIM: Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men. METHODS: Three randomized, single-blinded, placebo-controlled Phase 1 studies of mosliciguat DPI: a single-dose escalation study (SDES) of mosliciguat 60-4000 μg (n = 78), a multiple-dose escalation study (MDES) of seven once-daily doses of 480-2000 μg over 8 days (n = 36) and a multiple-dose study (MDS) of mosliciguat 1000 μg for 14 days (n = 21). RESULTS: Most adverse events (AEs) were mild, with no serious AEs or AEs leading to discontinuation. No clinically relevant lung function impairment or change in oxygen saturation was observed. In the MDES, body plethysmography indicated reduced airway resistance 6 h after dosing. Generally, no clinically relevant effect on blood pressure was seen; however, a few events of mild-to-moderate orthostatic hypotension occurred with higher doses in the SDES and MDS. In the SDES, there was a small, dose-dependent heart rate increase with mosliciguat. Increased plasma cyclic guanosine monophosphate levels confirmed target engagement by mosliciguat. Overall, the PK profile of mosliciguat was appropriate for an inhaled therapy, with low systemic exposures and an effect on airway resistance consistent with targeted inhaled lung-selective delivery. CONCLUSION: Mosliciguat DPI was well tolerated in healthy subjects, without AEs related to bronchospasm or airway irritation, with a pharmacodynamic response indicating sGC activation and a bronchodilating action. PMID: 42493842 | PMC: PMC13714609 | DOI: 10.1002/bcp.70668
引用
- PubMed 高证据 · 肺动脉高压:Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。